证券代码：688117 证券简称：圣诺生物 公告编号：2023-013 成都圣诺生物科技股份有限公司 关于召开 2022 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址 http://roadshow.sseinfo.com/） 本次投资者说明会以网络文字互动形式召开，公司将针对 2022 年年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开时间、地点 （一）会议召开时间：2023 年 5 月 4 日（星期四）上午 10:00-11:00 会议召开方式：上证路演中心网络文字互动 投资者可以于 2023 年 4 月 24 日(星期一)至 2023 年 4 月 28 日(星期五) 下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱（snkj@snbiopharm.com）进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 成都圣诺生物科技股份有限公司（以 ...

2022 年第三季度报告 证券代码：688117 证券简称：圣诺生物 成都圣诺生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 92,921,633.14 | 8.70 | 260,431,862. ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company reported a revenue of RMB 100 million for the first half of 2022, reflecting a year-on-year growth of 20%[12]. - The company has provided a revenue guidance of RMB 250 million for the full year 2022, representing a projected growth of 25%[12]. - The company reported a total revenue of 17,410.00 million RMB, with a net profit of 1,737.19 million RMB for the first half of 2022[65]. - The company reported a total revenue of 22,266.21 million with a net profit of 2,783.9 million for the first half of 2022[97]. - The company's operating revenue for the first half of the year was RMB 167.51 million, a decrease of 13.49% compared to the same period last year[21]. - Net profit attributable to shareholders was RMB 18.64 million, down 22.36% year-on-year, while the net profit after deducting non-recurring gains and losses was RMB 14.98 million, a decrease of 34.29%[21]. - Basic and diluted earnings per share were both RMB 0.23, reflecting a decline of 39.47% compared to the previous year[22]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2022[1]. - User data indicates an increase in active users by 15% compared to the previous period, reaching a total of 1.5 million active users[12]. - The company expects a revenue growth forecast of 25% for the second half of 2022, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[12]. Research and Development - Investment in R&D increased by 30% compared to the previous year, focusing on innovative drug development and technology enhancements[1]. - The company has invested RMB 50 million in R&D for new technologies, focusing on peptide-based drugs[12]. - Research and development expenses increased by 120.57% year-on-year, amounting to RMB 16.01 million, which impacted profitability[21]. - The proportion of R&D investment to operating revenue rose to 10.37%, an increase of 5.93 percentage points compared to the previous year[21]. - The total R&D investment increased by 102.18% year-on-year, reaching ¥17,371,595.03, driven by increased costs for the consistency evaluation of the project for Liraglutide injection and the initiation of the calcitonin project[57]. - The number of R&D personnel increased to 149, representing 19.68% of the total workforce[67]. - The company has 10 R&D products submitted for registration with the National Medical Products Administration, with 15 additional projects in mid to long-term research[70]. Product Development and Innovation - The company has launched two new products in Q2 2022, contributing to 15% of total sales during the period[1]. - The company has launched a new product line aimed at Type 2 diabetes patients, projected to generate RMB 30 million in revenue within the first year[12]. - The company is currently in the clinical trial phase for three new drugs, with expected completion of Phase III trials by Q4 2022[12]. - The company is actively involved in clinical research for various new drugs, including peptide injections for diabetes and cardiovascular diseases[32]. - The company has achieved significant milestones in the registration and approval of its products in both domestic and international markets[30]. - The company is committed to ongoing research and development to support its growth strategy and meet market demands[30]. Strategic Acquisitions and Partnerships - A strategic acquisition of a biotech firm is in progress, expected to enhance the company's product pipeline and market capabilities[1]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio, with a budget of RMB 200 million allocated for this purpose[12]. - The company has established partnerships with well-known pharmaceutical enterprises such as Fresenius, Aurobindo, and others, with raw material products sold in Europe, the United States, India, and South Korea[34]. - The company is exploring partnerships to enhance its research capabilities and accelerate the development of new therapies[64]. Financial Integrity and Compliance - The company has no non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[1]. - The company has received FDA approval for multiple products, including Linaclotide for treating constipation and Degarelix for advanced prostate cancer, with production values of 780.00 million RMB and 2,000.00 million RMB respectively[63]. - The company emphasizes compliance with environmental regulations, indicating a commitment to sustainability[106]. - The company has established a commitment to ensure that any share reduction does not exceed 2% of the total shares within a 90-day period if conducted through block trades[127]. Environmental Management - The company has established a dedicated environmental health and safety management department to effectively manage pollutants generated during production[110]. - The company has implemented strict management systems for solid waste and self-monitoring to minimize environmental impact[110]. - The company has constructed a wastewater treatment facility to ensure compliance with standards before discharging into municipal systems[119]. - The company has received environmental impact approvals for multiple projects, including peptide drug production lines and new drug research initiatives[114]. Shareholder Commitments and Regulations - The company has committed to a share lock-up period of 36 months from the date of listing, during which no shares will be transferred or managed by others[126]. - The actual controllers, Wen Yongjun and Ma Lanwen, have also agreed to a similar 36-month lock-up period for their shares[129]. - The company will comply with relevant regulations regarding share transfers and reductions as stipulated by the China Securities Regulatory Commission and the Shanghai Stock Exchange[129]. - Shareholders holding more than 5% of the company's shares are prohibited from transferring their shares within 12 months of the company's listing[135].

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year 2021, representing a growth of 25% compared to the previous year[18]. - The company reported a net profit of RMB 300 million, which is a 30% increase compared to the previous fiscal year[18]. - The company achieved operating revenue of CNY 386.53 million in 2021, representing a year-on-year growth of 2.05%[26]. - The net profit attributable to shareholders of the listed company was CNY 61.25 million, an increase of 2.09% compared to the previous year[26]. - The company reported a total revenue of 2,000.00 million for the year, with a growth rate of 52.88% compared to the previous year[85]. - The company reported a revenue of 1.2 billion in 2021, representing a year-over-year growth of 15%[180]. - The company provided a revenue guidance of 1.8 billion RMB for the next fiscal year, which reflects an expected growth of 20%[187]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling an estimated cash dividend of RMB 24 million, which represents 39.18% of the net profit attributable to shareholders for 2021[7]. - The profit distribution plan is subject to approval at the company's annual general meeting, highlighting the need for shareholder consent before implementation[8]. - The company confirmed the proposal for the distribution of profits for the year 2020 during the annual shareholder meeting[171]. Research and Development - The company focused on expanding its CDMO services and enhancing overseas business development during the reporting period[39]. - The company has developed core technologies in peptide drug CDMO services, including "single sulfur ring peptide large-scale production" and "long-chain peptide coupling technology" to enhance its market competitiveness in innovative drugs[40]. - The company is committed to ongoing research and development of new technologies and products to address unmet medical needs in various therapeutic areas[54]. - The company has established a robust pipeline of products in various stages of development, indicating strong future growth potential in the pharmaceutical market[54]. - The total R&D investment for the year was approximately ¥18.33 million, a decrease of 18.49% compared to the previous year[80]. - R&D investment accounted for 4.74% of total revenue, with a capitalization ratio of 25%[145]. Market Expansion and Strategy - The company is expanding its market presence, targeting an increase in market share by 10% in the Asia-Pacific region over the next two years[18]. - The company is exploring new strategies for market expansion, including potential mergers and acquisitions to enhance its product offerings and market reach[54]. - Market expansion plans include entering three new international markets by the end of 2022[182]. - The company aims to strengthen its product development and technology platform, focusing on key areas such as oncology, diabetes, obstetrics, digestive system, and immune system diseases[157]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, indicating a stable governance structure[11]. - The company has not violated decision-making procedures for external guarantees, reinforcing its compliance with regulations[11]. - The company maintained compliance with legal and regulatory requirements in all shareholder meetings[172]. - The company has not engaged in any related party transactions during the reporting period[174]. Risks and Challenges - The company has outlined various risks in its operations and has provided measures to address these risks, emphasizing the importance of investor awareness[5]. - The report includes a forward-looking statement risk declaration, cautioning investors about the uncertainties in future plans and strategies[10]. - The company faces risks related to research and development failures, which could lead to loss of competitive advantage if products do not meet regulatory approval[98]. - The company is exposed to financial risks, including potential issues with accounts receivable collection and foreign exchange fluctuations due to international operations[100]. Operational Efficiency - The gross margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[18]. - The company has successfully reduced operational costs by 15% through efficiency improvements in the supply chain[187]. - The company reported a significant increase in technical service costs, which rose by 22.65% year-on-year to 1.97 million RMB[113]. Shareholder Engagement - The company held a total of 3 shareholder meetings during the reporting period, including 1 annual meeting and 2 extraordinary meetings[172]. - The board of directors and senior management did not experience any changes in shareholding during the reporting period, with all key personnel maintaining their shareholdings[174]. - The total pre-tax remuneration for the chairman and general manager, Wen Yongjun, was 640,800 RMB[174].

Revenue and Profit - Revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.44% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 14,292,867.60, an increase of 22.64% year-over-year[6] - Total operating revenue for Q1 2022 was CNY 80,744,800.39, a decrease of 13.4% compared to CNY 93,280,186.12 in Q1 2021[18] - The company reported a net profit of CNY 14,797,683.82 for Q1 2022, compared to a net profit of CNY 13,284,381.40 in Q1 2021[18] - The net profit for Q1 2022 was CNY 14,292,867.60, an increase of 22.3% compared to CNY 11,653,981.88 in Q1 2021[19] - Operating profit for Q1 2022 reached CNY 17,636,111.54, up from CNY 14,153,914.49 in the same period last year, reflecting a growth of 24.3%[19] - The total comprehensive income for Q1 2022 was CNY 14,292,867.60, up from CNY 11,653,981.88 in Q1 2021, reflecting an increase of 22.3%[20] Expenses and Costs - R&D expenses totaled CNY 6,108,108.78, representing 7.56% of revenue, an increase of 1.6 percentage points[7] - Total operating costs for Q1 2022 were CNY 65,947,116.57, down 17.5% from CNY 79,995,804.72 in Q1 2021[18] - Research and development expenses for Q1 2022 were CNY 5,112,082.43, slightly up from CNY 5,011,994.78 in Q1 2021[18] - The company incurred a credit impairment loss of CNY 429,227.24 in Q1 2022, compared to CNY 624,004.03 in Q1 2021, showing a decrease of 31.2%[19] - The company incurred financial expenses of CNY 267,075.46 in Q1 2022, contrasting with a financial income of CNY 252,479.62 in Q1 2021[25] Cash Flow and Liquidity - Operating cash flow for the quarter was CNY 29,565,224.06, up 20.12% from the previous year[7] - Cash flow from operating activities generated a net amount of CNY 29,565,224.06, compared to CNY 24,612,688.81 in Q1 2021, indicating a year-over-year increase of 20.0%[21] - Total cash and cash equivalents at the end of Q1 2022 amounted to CNY 268,158,720.07, significantly higher than CNY 135,737,596.01 at the end of Q1 2021, representing an increase of 97.5%[21] - The company reported cash inflows from investment activities of CNY 201,170,235.62, with a net cash flow from investment activities of CNY 19,110,356.37, compared to a net outflow of CNY 17,353,559.51 in Q1 2021[21] - The company's cash outflow from operating activities totaled CNY 126,590,112.56 in Q1 2022, compared to CNY 110,059,935.17 in Q1 2021, indicating an increase of 15.1%[21] Assets and Liabilities - Total assets at the end of the quarter were CNY 992,618,993.49, an increase of 3.76% from the end of the previous year[7] - Cash and cash equivalents as of March 31, 2022, were CNY 269,428,720.07, an increase from CNY 211,564,862.66 as of December 31, 2021[14] - Inventory as of March 31, 2022, was CNY 113,310,556.00, up from CNY 101,363,001.75 as of December 31, 2021[15] - Total liabilities as of March 31, 2022, were CNY 192,911,128.84, an increase from CNY 171,480,668.76 as of December 31, 2021[16] - The company’s total equity as of March 31, 2022, was CNY 799,707,864.65, compared to CNY 785,137,100.85 as of December 31, 2021[17] Shareholder Information - The company reported a total of 6,406 common shareholders at the end of the reporting period[10] - The largest shareholder, Chengdu Sainuo Investment Co., Ltd., holds 30,000,000 shares, representing 37.5% of total shares[10] Other Financial Metrics - Basic and diluted earnings per share were both CNY 0.18, a decrease of 5.26% compared to the same period last year[7] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.18, slightly down from CNY 0.19 in Q1 2021[20] - The company’s total equity as of the end of Q1 2022 was CNY 509,521,123.28, compared to CNY 509,328,982.40 at the end of Q1 2021[25]

Financial Performance - The company's operating revenue for Q3 2021 was ¥85,482,938.78, a decrease of 10.19% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥19,024,936.15, an increase of 83.89% year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥18,352,139.50, up 93.81% compared to the previous year[5]. - Net profit for the third quarter of 2021 was ¥43,033,916.95, compared to ¥41,656,637.29 in the previous year, representing a growth of approximately 3.3%[23]. - Total operating revenue for the first three quarters of 2021 reached ¥279,121,290.27, an increase from ¥270,905,465.33 in the same period of 2020, reflecting a growth of approximately 0.8%[22]. - Total operating costs for the same period were ¥230,546,720.25, up from ¥223,621,046.30, indicating an increase of about 3.9%[22]. - Basic earnings per share for the reporting period were ¥0.24, an increase of 41.18% year-on-year[6]. - Basic and diluted earnings per share for the third quarter were both ¥0.62, down from ¥0.69 in the same quarter of the previous year[24]. - The company reported a financial income of ¥2,594,587.88, up from ¥1,454,015.01, showing an increase of about 78.3%[22]. - The total comprehensive income for the third quarter was ¥43,033,916.95, consistent with the net profit, indicating no other comprehensive income adjustments[24]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥907,425,796.89, reflecting a growth of 53.03% from the end of the previous year[6]. - As of September 30, 2021, the total current assets amounted to ¥602,984,005.70, a significant increase from ¥336,093,024.41 at the end of 2020, representing an increase of approximately 79.5%[16]. - The total assets of the company as of September 30, 2021, were ¥907,425,796.89, compared to ¥592,984,864.45 at the end of 2020, reflecting an increase of approximately 53.1%[17]. - The company reported a total non-current assets of ¥304,441,791.19, up from ¥256,891,840.04, which is an increase of around 18.4%[17]. - The company's total liabilities decreased from ¥155,410,598.68 to ¥140,785,431.76, a reduction of about 9.4%[22]. - The total liabilities were not explicitly stated, but accounts payable decreased to ¥5,257,078.05 from ¥20,666,627.10, indicating a reduction of approximately 74.6%[17]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥28,604,702.44, down 53.65% compared to the previous year[6]. - Cash inflows from operating activities totaled ¥396,307,890.00 for the first three quarters, compared to ¥370,248,224.86 in the same period of 2020, reflecting an increase of about 7.0%[25]. - The net cash flow from operating activities was $28,604,702.44, a decrease of 53.8% compared to $61,720,516.49 in the previous year[26]. - Total cash outflow from operating activities amounted to $367,703,187.56, up 19.1% from $308,527,708.37 year-over-year[26]. - The net cash flow from investing activities was -$63,765,550.05, compared to -$39,790,550.95 in the same period last year, indicating a significant increase in investment outflows[26]. - Cash inflow from financing activities was $285,016,000, with no cash inflow recorded in the previous year[26]. - The net cash flow from financing activities was $285,016,000, contrasting with a net outflow of $475,309.33 in the previous year[26]. - The total cash and cash equivalents at the end of the period reached $377,808,156.41, a substantial increase from $124,263,977.90 year-over-year[27]. - The cash and cash equivalents net increase for the quarter was $249,551,678.76, compared to $21,314,496.95 in the same quarter last year[27]. - The company reported a cash outflow of $63,765,550.05 from investing activities, primarily due to capital expenditures[26]. Research and Development - Research and development expenses totaled ¥3,418,356.09, a decrease of 58.57% compared to the same period last year[6]. - Research and development expenses for the third quarter were ¥8,920,158.71, a decrease from ¥11,936,006.06 in the previous year, indicating a reduction of approximately 25.3%[22]. - The company has 27 self-developed projects, with 11 projects completed and entering the review stage or about to be reported, and 5 projects in clinical trial stages[10]. - The company has ongoing development expenditures amounting to ¥7,826,561.29, which increased from ¥4,736,120.07, reflecting a growth of about 65.5%[17]. Shareholder Information - The top shareholder, Chengdu Sainuo Investment Co., Ltd., holds 37.50% of the shares, totaling 30,000,000 shares[12]. - The company has no reported financing or margin trading activities among the top shareholders[13].

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company expects a revenue growth forecast of 25% for the second half of 2021, driven by new product launches and market expansion strategies[1]. - ChengDu Sheng Nuo Biotec Co., Ltd. reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 100 million, representing a 25% growth compared to the same period in 2020[15]. - Future outlook indicates a projected revenue growth of 20% for the second half of 2021, driven by new product launches and market expansion strategies[15]. - The company's operating revenue for the reporting period (January to June) was CNY 193,638,351.49, an increase of 10.20% year-on-year[23]. - The net profit attributable to shareholders was CNY 24,008,980.80, a decrease of 23.32% compared to the same period last year[24]. - The net cash flow from operating activities decreased by CNY 37,183,863.49, primarily due to increased purchases of raw materials and higher market promotion expenses[25]. - The net assets attributable to shareholders increased by 70.79% to CNY 747,337,532.78, and total assets rose by 55.25% to CNY 920,595,710.10, mainly due to funds raised from the IPO[26]. - Basic and diluted earnings per share decreased by 26.92% to CNY 0.38, impacted by the dilution effect from the issuance of 20 million shares[28]. - The company achieved a sales revenue of 193.64 million RMB, representing a year-on-year growth of 10.20%[98]. - Operating costs increased by 20.39% to 47.29 million RMB, primarily due to rising costs in pharmaceutical research and recycled chemical reagents[98]. - Net profit attributable to shareholders decreased by 23.32% to 24.01 million RMB, while the net profit excluding non-recurring gains and losses fell by 22.17% to 22.79 million RMB[98]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2021[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - The company has expanded its user base, with active users increasing by 30% year-over-year, now totaling 500,000 users[15]. - The company plans to enhance its distribution network, targeting a 20% increase in market penetration by the end of 2022[15]. Research and Development - Research and development expenses increased by 30% compared to the previous year, focusing on innovative biopharmaceutical products[1]. - The company is actively developing innovative drugs, with three new drug candidates expected to enter clinical trials by the end of 2021[15]. - Research and development expenses have increased by 10%, reflecting the company's commitment to innovation and product development[15]. - The company invested 4.44% of its operating revenue in R&D, an increase of 0.81 percentage points year-on-year[22]. - Total R&D investment increased by 34.87% year-on-year, reaching ¥8,592,243.84, driven by clinical trial approvals for key projects[81]. - The proportion of R&D investment capitalized increased by 14.24 percentage points, reflecting the progress of clinical trials for key projects[82]. - The company has provided pharmaceutical research services for over 30 innovative peptide drug projects, with 1 approved for market and 7 in clinical trial stages[74]. - The company has ongoing projects with 10 varieties submitted for registration and 3 varieties granted clinical trial approval, indicating a strong pipeline for future products[118]. Operational Efficiency and Cost Management - The company has implemented new strategies to improve operational efficiency, aiming for a 15% reduction in production costs by the end of 2021[1]. - The company has established a robust quality management system in compliance with GMP standards to ensure consistent production quality[46]. - The production process adheres to GMP standards, with rigorous quality control measures in place throughout the manufacturing cycle[56]. - The company has made significant investments in pollution control facilities and production process optimization to minimize environmental impact[142]. Risk Factors and Challenges - The company has identified several risk factors, including regulatory changes and market competition, which may impact future performance[1]. - The decline in net profit was attributed to limited production capacity due to the need to meet GMP conditions for CDMO services[24]. - The average price drop for drugs due to centralized procurement is approximately 52%-53%, which poses a risk to the sustainability of the company's formulation sales[108]. - The company faces risks of declining sales revenue for its main API, Bevacizumab, if its major client, Fresenius, loses market share in the U.S.[109]. - The company faces risks related to R&D failures, market acceptance of new products, and potential loss of core technical personnel, which could impact future performance[120][121][122]. Environmental Compliance and Sustainability - The company emphasizes strict compliance with environmental laws and has implemented effective management of pollutants generated during production[142][143]. - The company has established emergency response plans for environmental incidents, which have been registered with the Chengdu Deyang County Ecological Environment Bureau[146][148]. - The company has not experienced any environmental pollution incidents or received administrative penalties from environmental authorities during the reporting period[143]. - The company has committed to maintaining a lock-up period for major shareholders, preventing the transfer of shares for 36 months post-IPO[158]. - The company has a focus on environmental protection and sustainable practices, aligning with national and industry standards[153]. Shareholder Commitments and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, with a two-year lock-up period for any reductions thereafter[161]. - The company will adhere to the regulations set forth by the China Securities Regulatory Commission regarding share transfers and reductions[165]. - The company has established measures to avoid competition among its major shareholders and related parties, ensuring a clear operational focus[191]. - The company has made commitments regarding the handling of non-operating fund occupation by major shareholders and related parties, ensuring compliance with regulations[192].